FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	urden
houre por rosponso	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response:															
1. Name and Address of Reporting Person* MOOS WALTER H				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2011							-	Officer (g	ive title below)	Other	(specify below)	
(Street) SOUTH SAN FRANCISCO, CA 94025-3493				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	y)	(State)	(Zip)			Ta	ble I -	- Non-Deri	vative Se	ecuritie	s Acquir	red, Dispose	d of, or Bend	eficially Owned	ı	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					, if C	3. Transaction Code (Instr. 8)		4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Follow		wing Reporte	ed O Fo D	wnership orm: Be irect (D) Ov	Nature Indirect eneficial wnership astr. 4)	
							Code	e V	mount	(A) or (D)	Price			(I (I	nstr. 4)	
											•		d unless th number.	e form		
								display	s a curi	rently vor Bene	valid ON	MB contro		e form		
1. Title of Derivative Security (Instr. 3)	Conversion		3A. Deemed Execution Date, if	4. Transac Code	ts, calls 5. tion of Se or of (Ir	warr Numb	er ative s l (A) sed	display	osed of, onvertible ercisable Date	rently vor Benees securion	valid OM	Owned and Amounterlying lies	number.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	Beneficia
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	ts, calls tion of Se Acor of (Ir an	Numb Deriva curitie quired Dispos (D) str. 3,	er ntive s l (A) sed 4,	display	osed of, onvertible ercisable Date y/Year)	rently vor Benees e securi	ficially (ities) 7. Title of Under Securiti	Owned and Amounterlying lies	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficia Ownersh

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MOOS WALTER H C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94025-3493	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/20/2011
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.